RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Tot Biopharm, a Suzhou oncology company backed by Chengwei Capital, filed to IPO on the Hong Kong Exchange. The company has developed a portfolio of more than ten candidates including three biologics and three small molecule drugs that are approved to conduct China clinical trials. Founded in 2010, Tot has raised a total of $108 million, most of which was a $102 million Series B funding, completed in 2018 and led by 99 Fund and China Universal.
Source: China Biotoday
